Endocrine

, Volume 26, Issue 1, pp 19–24 | Cite as

Serum levels of leptin, insulin, and lipids in relation to breast cancer in China

  • Cunzhi Han
  • Hong-Tao Zhang
  • Lili Du
  • Xiuying Liu
  • Jiexian Jing
  • Xianwen Zhao
  • Xuan Yang
  • Baoguo Tian
Original Articles

Abstract

Epidemiological studies have found obesity to be a risk factor for women’s breast cancer. The present study was to investigate whether there is a relationship between serum levels of leptin, insulin, and lipids and breast cancer incidence, in order to find experimental evidence that would be helpful in the diagnosis and prevention of breast cancer. Blood samples were collected from 130 patients with mammary disease and 103 healthy control subjects. Serum leptin, insulin, and lipids were determined by radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISA), and Biochemistry Auto-analyzer, respectively. The data analysis was performed by use of the SPSS10.0 computer software. We found that the serum levels of leptin, insulin, and triglyceride (TG) were clearly higher in patients with breast cancer than in patients with benign breast disease and healthy controls, while serum HDL-Clevels were lower in breast cancer patients (p<0.03). Moreover, serum leptin levels were significantly correlated with BMI (body mass index) among three groups, whereas serum insulin levels were unrelated to BMI among three groups. Furthermore, the serum levels of leptin and insulin were not associated with menopausal status in patients with mammary disease (p>0.05); however, the serum levels of F-Chol, T-Chol, TG, LDL-C, and APOB were significant higher in postmenopausal cases than those in premenopausal cases (p<0.025). Interestingly, logistic regression analysis showed that subjects with elevated serum levels of leptin, insulin, TG, APOA1, and reduced level of serum HDL-C displayed increased risk of developing breast cancer than those with the normal levels, respectively. In conclusion, the present study suggested that aberrant serum levels of leptin, insulin, and lipids might play an important role in carcinogenesis of breast cancer. The elevated serum levels of leptin, insulin, TG, APOA1, and reduced level of serum HDL-C may be correlated with increased risk of breast cancer, suggesting that one way of preventing breast cancer would be carried out by controlling the intake of food.

Key Words

Breast cancer leptin insulin lipids serum levels 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal, A., Tiwari, R. C., Murray, T., et al., and American Cancer Society (2004). CA Cancer J. Clin. 54, 8–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Liu, G. J. and Qiu, W. J. (2003). Acta Medicinae Sinica 16, 599–601.Google Scholar
  3. 3.
    Tessitore, L., Vizio, B., Jenkins, O., et al. (2000). Int. J. Mol. Med. 5, 421–426.PubMedGoogle Scholar
  4. 4.
    O’Brien, S. N., Welter, B. H., and Price, T. M. (1999). Biochem. Biophys. Res. Commun. 259, 695–698.PubMedCrossRefGoogle Scholar
  5. 5.
    Hardwick, J. C., Van Den Brink, G. R., Offerhaus, G. J., Van Deventer, S. J., and Peppelenbosch, M. P. (2001). Gastroenterology 121, 79–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Stattin, P., Lukanova, A., Biessy, C., et al. (2004). Int. J. Cancer 109, 149–152.PubMedCrossRefGoogle Scholar
  7. 7.
    Somasundar, P., Yu, A. K., Vona-Davis, L., and McFadden, D. W. (2003). J. Surg. Res. 113, 50–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Frankenberry, K. A., Somasundar, P., McFadden, D. W., and Vona-Davis, L. C. (2004). Am. J. Surg. 188, 560–565.PubMedCrossRefGoogle Scholar
  9. 9.
    Hsing, A. W., Chua, S. Jr., Gao, Y. T., et al. (2001). J. Natl. Cancer Inst. 93, 783–789.PubMedCrossRefGoogle Scholar
  10. 10.
    Niskanen, L. K., Haffner, S., Karhunen, L. J., Turpeinen, A. K., Miettinen, H., and Uusitupa, M. I. (1997). Eur. J. Endocrinol. 137, 61–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Larsson, H., Elmstahl, S., and Ahren, B. (1996). Diabetes 45, 1580–1584.PubMedCrossRefGoogle Scholar
  12. 12.
    Segal, K. R., Landt, M., and Klein, S. (1996). Diabetes 45, 988–991.PubMedCrossRefGoogle Scholar
  13. 13.
    Johannsson, G., Karlsson, C., Lonn, L., et al. (1998). Obes. Res. 6, 416–421.PubMedGoogle Scholar
  14. 14.
    Ho, S. C., Tai, E. S., Eng, P. H., Ramli, A., Tan, C. E., and Fok, A. C. (1999). Int. J. Obes. Relat. Metab. Disord. 23, 246–252.PubMedCrossRefGoogle Scholar
  15. 15.
    Asseryanis, E., Ruecklinger, E., Hellan, M., Kubista, E., and Singer, C. F. (2004). Gynecol. Endocrinol. 18, 29–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Sauter, E. R., Garofalo, C., Hewett, J., Hewett, J. E., Morelli, C., and Surmacz, E. (2004). Horm. Metab. Res. 36, 336–340.PubMedCrossRefGoogle Scholar
  17. 17.
    Hu, X., Juneja, S. C., Maihle, N. J., and Cleary, M. P. (2002). J. Natl. Cancer Inst. 94, 1704–1711.PubMedGoogle Scholar
  18. 18.
    Resta, F., Triggiani, V., Sabba, C., et al. (2004). Curr. Drug Targets Immune Endocr. Metabol. Disord. 4, 327–333.PubMedCrossRefGoogle Scholar
  19. 19.
    Macinnis, R. J., English, D. R., Gertig, D. M., Hopper, J. L., and Giles, G. G. (2004). Cancer Epidemiol. Biomarkers Prev. 13, 2117–2125.PubMedGoogle Scholar
  20. 20.
    Del Giudice, M. E., Fantus, I. G., Ezzat, S., McKeown-Eyssen, G., Page, D., and Goodwin, P. J. (1998). Breast Cancer Res. Treat. 47, 111–120.PubMedCrossRefGoogle Scholar
  21. 21.
    Hirose, K., Toyama, T., Iwata, H., Takezaki, T., Hamajima, N., and Tajima, K. (2003). Asian Pac. J. Cancer Prev. 4, 239–246.PubMedGoogle Scholar
  22. 22.
    Lahti, E. I., Knip, M., and Laatikainen, T. J. (1994). Cancer 74, 618–624.PubMedCrossRefGoogle Scholar
  23. 23.
    Jerome, L., Shiry, L., and Leyland-Jones, B. (2004). Semin. Oncol. 31, 54–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Voskuil, D. W., Bosma, A., Vrieling, A., Rookus, M. A., and van’t Veer, L. J. (2004). Breast Cancer Res. Treat. 84, 225–233.PubMedCrossRefGoogle Scholar
  25. 25.
    Mantzoros, C. S., Bolhke, K., Moschos, S., and Cramer, D. W. (1999). Int. J. Cancer. 80, 523–526.PubMedCrossRefGoogle Scholar
  26. 26.
    Petridou, E., Papadiamantis, Y., Markopoulos, C., Spanos, E., Dessypris, N., and Trichopoulos, D. (2000). Cancer Causes Control 11, 383–388.PubMedCrossRefGoogle Scholar
  27. 27.
    Chu, N. F., Spiegelman, D., Hotamisligil, G. S., Rifai, N., Stampfer, M., and Rimm, E. B. (2001). Atherosclerosis 157, 495–503.PubMedCrossRefGoogle Scholar
  28. 28.
    Garaulet, M., Viguerie, N., Porubsky, S., et al. (2004). J. Clin. Endocrinol. Metab. 89, 756–760.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  • Cunzhi Han
    • 1
  • Hong-Tao Zhang
    • 2
  • Lili Du
    • 1
  • Xiuying Liu
    • 1
  • Jiexian Jing
    • 1
  • Xianwen Zhao
    • 1
  • Xuan Yang
    • 1
  • Baoguo Tian
    • 1
  1. 1.Department of etiologyShanxi Cancer InstituteTaiyuanP. R. China
  2. 2.Laboratory of Medical Genetics, School of Life SciencesSuzhou UniversitySuzhouP. R. China

Personalised recommendations